Key Stats for Live Nation Stock
- Current Price: $180.22
- Target Price (Mid): ~$310
- Street Target (Mean): ~$190
- Street High Target: $222 (Wells Fargo, July 9, 2026)
- Potential Total Return: ~73%
- Annualized IRR: ~13% / year
- Max Drawdown: 27.84% on 11/24/25
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Live Nation Entertainment (LYV) spent most of the last two years priced like a company waiting on a verdict. That verdict came in April, and it went against them. A federal jury found the company and Ticketmaster liable on every antitrust count. Three of Wall Street’s biggest names spent the second week of July raising their price targets, and the shares touched an all-time high of $188 on July 6 before easing back to $180.22.
That is the disconnect worth sitting with. The people paid to model this business are getting more bullish at the exact moment the legal risk is most concrete, because a remedy phase that could still reshape Ticketmaster has not been decided. The bull case is not that the lawsuit disappeared. It is that the operating business is running well enough to outrun it.
Three Banks Raised Targets in a Single Week, One to $222
The July cluster was tight and one-directional. On July 9, Wells Fargo analyst Steven Cahall kept an Overweight rating and lifted his target to $222 from $199, the highest published number on the Street. The same day, Goldman Sachs analyst Stephen Laszczyk maintained a Buy and moved to $202 from $192. Six days later, on July 15, Roth Capital reiterated a Buy and raised its target to $205 from $190.
Three firms, three increases, no downgrades in the batch. But read the full tape before reading that as a green light. The mean Street target sits at around $190 on the TIKR Street Targets page, only about 4% above the current $180.22, so consensus is far more cautious than the $222 top end suggests. The exact recommendation split is 17 Buys, 3 Outperforms, 2 Holds, 1 Underperform, and 1 Sell. The skeptics have not left the building, and one analyst still rates it a Sell.
See historical and forward estimates for Live Nation stock (It’s free!) >>>
Why the Operating Business Is Doing the Heavy Lifting
The reason analysts can raise targets into a liability verdict is that the demand data has not blinked, and the economics of the venues keep improving underneath it. At the J.P. Morgan Technology, Media and Communications Conference on May 20, President and CFO Joe Berchtold walked through how much the amphitheater business has changed. On-site spending per fan has climbed from roughly $16 per cap to around $46, he said, as food, beverage, and premium offerings have expanded. That shift matters because it means Live Nation can open venues to third-party promoters, as the settlement requires, and still grow profit on the operations side even if it promotes fewer of those shows itself.
Berchtold also pushed back on the idea that concerts are pricing fans out. He noted that the average get-in price across the U.S. shows is around $34 to $35, up roughly 18% from 2019, while general inflation ran closer to 30% over the same stretch. That is the affordability argument the company keeps returning to, and it is central to why management believes attendance can keep compounding.
The full-year 2025 numbers give the demand story a frame. Revenue reached $25.2 billion, up about 9% year over year, and the segment detail shows where the scale sits: Concerts contributed $20.9 billion in operating revenue, and Sponsorship & Advertising, the highest-margin piece, added $1.3 billion. The operating margin story is really a mix story, where sponsorship and premium experiences carry the profitability, even as concerts carry the volume.
See how Live Nation performs against its peers in TIKR (It’s free!) >>>
The Verdict Is Real, and the Remedy Is Still Open
Here is where the caution belongs, stated plainly. In March 2026, the DOJ settled with Live Nation mid-trial without forcing a Ticketmaster breakup. Under that deal, the company agreed to divest its 13 exclusive amphitheater booking agreements while continuing to operate those venues as open ones, cap service fees at Live Nation-owned amphitheaters at 15%, let promoters distribute up to 50% of primary tickets through rival marketplaces, cap exclusive ticketing contracts at four years, and fund a settlement pool of roughly $280 million. Thirty-three states and the District of Columbia rejected the settlement and continued the trial. On April 15, the jury found Live Nation liable on all of the states’ claims.
Berchtold’s framing at J.P. Morgan explains why management is not treating the settlement terms as a wound. On relaxing Ticketmaster’s exclusivity, he said the company is content to let the market decide, arguing most venues will still choose Ticketmaster because it is the better product. “We continue to believe that most venues are going to want exclusivity, and they’re going to want that exclusivity to be with us,” he said. If he is right, the remedies dent the optics more than the economics. If the states are right that exclusivity was the moat, the remedies matter a great deal. That unresolved bet is the whole story.
On valuation, the stock is not obviously cheap on any current-profit measure, because there is barely any current normalized profit to divide into. Normalized EPS was negative in 2025 under litigation and venue preopening costs, which makes the trailing P/E ratio meaningless. The market is paying for the recovery, not the print. On a forward basis, LYV trades at around 16.7x NTM (next twelve months) EV/EBITDA. For scale, Madison Square Garden Sports (MSGS) screens far higher near 169x on that same forward EBITDA basis, on a much smaller revenue base, while European operator CTS Eventim trades at a fraction of LYV’s multiple. The premium is the price of Live Nation’s global buildout and Ticketmaster’s scale, and whether it is justified rests almost entirely on the remedy phase clearing without structural damage.
TIKR Advanced Model Analysis
- Current Price: $180.22
- Target Price (Mid): ~$310
- Potential Total Return: ~73%
- Annualized IRR: ~13% / year
See analysts’ growth forecasts and price targets for Live Nation stock (It’s free!) >>>
Using the mid-case scenario realized at year-end 2030, the TIKR Valuation Model puts fair value at around $310, a total return of roughly 73% over the next four and a half years, or about 13% annualized. The mid case is the right anchor because it neither assumes the legal cloud vanishes overnight nor prices in a forced breakup; it reflects the business roughly as it operates today.
Two revenue drivers carry the forecast. The first is international expansion, where Berchtold noted that 47 of the top 75 cities outside the U.S. either lack a modern arena or are underpenetrated, giving Venue Nation years of runway. The second is Ticketing growth tied directly to concert volume, with fee-bearing tickets and gross transaction value both rising as the global show pipeline grows. The margin driver is the mix shift toward sponsorship and premium experiences, the highest-margin revenue in the model. The primary risk is the remedy phase producing structural relief that breaks the Ticketmaster-to-concerts flywheel.
The upside: if the remedy lands consistent with the DOJ settlement and international venues ramp on schedule, the stock compounds toward the mid-case target. The downside: a structural remedy or a demand rollover would compress the multiple back toward peers and take the recovery thesis with it.
Conclusion
The next hard checkpoint is Q2 earnings after the close on July 30. Watch two things. First, the ticket-sales pace and per-cap spending: management has said on-site spending is running up, and any wording about softening sell-through would be the first real crack in the demand thesis. Second, any update on the remedy timeline from Judge Subramanian’s court, because that is the variable the whole multiple hinges on. Good looks like double-digit deferred revenue growth and no adverse remedy signal. Bad looks like decelerating ticket volume paired with the states gaining traction on structural relief. Until the remedy is set, the analysts raising targets and the lone Sell rating are both making the same bet from opposite sides, and July 30 is the next time the data votes.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Live Nation?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Live Nation, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Live Nation alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Live Nation on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
